According to Fintel, on May 25, 2023, HC Wainwright & Co. reiterated their coverage of Alimera Sciences with a Buy recommendation. The average one-year price target for Alimera Sciences is $7.31, as of May 11, 2023. This represents an increase of 187.80% from its latest reported closing price of $2.54.
There are currently 34 funds or institutions reporting positions in Alimera Sciences. This is a decrease of 6 owners or 15.00% in the last quarter. The average portfolio weight for all funds dedicated to ALIM is 0.04%, a decrease of 25.32%. Total shares owned by institutions decreased in the last three months by 8.97% to 2,135K shares.
Some of the major shareholders of Alimera Sciences include Caligan Partners, Velan Capital Investment Management, Healthcare Of Ontario Pension Plan Trust Fund, and Renaissance Technologies.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. The company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.
Key filings for this company can be found on Fintel.
Note: The views and opinions expressed in this article are solely those of the author and do not reflect the views of Nasdaq, Inc.
